Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Phase 2 Completed 71 enrolled UCB Pharma

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 \[NCT00245765\] and Week 12 of re-treatment in this study.

Timeline

Start: 2006-04
Primary completion: 2007-05
Completion: 2007-05

Outcome

Met primary endpoint

paper PASI 75 was achieved by 44/59 (75%), 48/58 (83%) and 4/59 (7%) patients PMID 22413944 ↗

paper in the CZP 200 mg, CZP 400 mg and placebo groups, respectively (P < 0·001 for both treatment arms vs. placebo). PMID 22413944 ↗

paper A PGA score of clear-almost clear was achieved by 53%, 72% and 2%, respectively (P < 0·001 for both treatment arms vs. placebo). PMID 22413944 ↗

Publications

Results Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Certolizumab Pegol	Protein / enzyme biologic	200 mg	Subcutaneous
Subject	Certolizumab Pegol	Protein / enzyme biologic	400 mg	Subcutaneous